Alphamab Oncology
Status: Publicly traded
Direct answer
Alphamab Oncology is publicly traded on HKSE under the ticker 9966.HK.
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the...
Can you invest in Alphamab Oncology?
Yes. Alphamab Oncology trades publicly on HKSE as 9966.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Alphamab Oncology
Detailed equity research is provided by MarketSnap.